27. Deutscher Krebskongress
Deutsche Krebsgesellschaft e. V.
22. - 26.03.2006, Berlin
Breast Cancer (Systemic and Supportive Therapy)
Meeting Abstract
(OP023)
[Volltext]
HER2 expression in disseminated tumor cells and corresponding primary tumors of primary breast cancer patients
Fehm T, Bachmann R, Pergola G, Wallwiener D, Vogel U, Solomayer E, Becker S[Volltext]
Meeting Abstract
(OP024)
[Volltext]
Significant survival benefit of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: results from 979 women enrolled in the ARNO 95 trial
Kaufmann M, Jonat W[Volltext]
Meeting Abstract
(OP025)
[Volltext]
Lymphedema inbreast cancer patients - Consensus recommendations for the postoperative management of breast cancer patients
Seifart U, Albert U, Heim ME, Hübner J, Jungkunz W, Prokein R, Rick O, Hoffmann A, Engenhart-Cabillic R, Kopp I, Wagner U, Kalder M[Volltext]
Meeting Abstract
(OP026)
[Volltext]
Molecular risk estimation and adjuvant chemotherapy in node-negative breast cancer patients - a status report of the prospective clinical trial NNBC 3-Europe
Paepke D, Herbst F, Annecke K, Gaskill N, Sweep F, Augustin D, Meisner C, Schmidt M, Schmitt M, Jaenicke F, Harbeck N, Thomssen C[Volltext]
Meeting Abstract
(OP027)
[Volltext]
Prescription Pattern of Aromatase Inhibitors for the Adjuvant Therapy of Breast Cancer in Germany – Results of the Second Survey Among Gynecologists and Medical Internists
Lüftner D, Scheller J, Henschke P, Possinger K[Volltext]
Meeting Abstract
(PO028)
[Volltext]
Chemotherapy induced nausea and vomitus (CINV) depends on pharmacogenetisc of the 5-HT-3-Receptor
Kollmansberger B, Lux MP, Beckmann K, Schrauder M, Strissel P, Strick R, Beckmann MW, Fasching PA[Volltext]
Meeting Abstract
(PO029)
[Volltext]
Long term follow up of sequential dose dense chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) in breast cancer patients with 4-9 positive lymph nodes: final results of a phase I/II study
Möbus V, Hauser N, Kurbacher C, Lück H, Thomssen C, Nitz U, Kreienberg R, Untch M[Volltext]
Meeting Abstract
(PO030)
[Volltext]
Adjuvant chemotherapy of brest cancer: A comparison of 4 standardschemes with regard to praciticability/feasibility and toxicity. An evaluation of the quality assurance project Gynaecological Oncology
Henning K[Volltext]
Meeting Abstract
(PO031)
[Volltext]
Randomized controlled trial of the feasibility and effects of a structural training program in the rehabilitation of breast cancer patients with fatigue
Elsner von der Malsburg M, Heim M, Niklas A[Volltext]
Meeting Abstract
(PO032)
[Volltext]
Sorafenib (BAY 43-9006) in patients with metastatic breast cancer - a Phase II multicentre open trial
Loibl S, Bianchi G, Zamagni C, Ardizzoni A, Raab G, Siena S, Wolf C, Westermeier T, Bergamini L, Gianni L, Kaufmann M[Volltext]
Meeting Abstract
(PO033)
[Volltext]
Darbepoetin alfa as primary prophylaxis of anaemia in breast cancer patients treated preoperatively with Docetaxel, Doxorubicin, Cyclophosphamide
Marquardt F, Loibl S, von Minckwitz G, Kaufmann M[Volltext]
Meeting Abstract
(PO034)
[Volltext]
Physicians’ Treatment Strategies in Breast Cancer Chemotherapy: The BEAM Drug Utilization Study in Germany
Bauknecht T, Helsberg K, Kessler F, Langer F, Nicolay C, Jackisch C[Volltext]
Meeting Abstract
(PO035)
[Volltext]
CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor–positive breast cancer in premenopausal patients: a randomised, trial (GABG trial IV-A-93)
Vescia S, Graf E, Geberth M, Eiermann W, Jonat W, Conrad B, Brunnert K, Gerber B, Kaufmann M, von Minckwitz G[Volltext]
Meeting Abstract
(PO036)
[Volltext]
Multi-center Validation of a Gene Expression Based Prognostic Signature in Lymph Node-Negative Primary Breast Cancer
Schmitt M, Foekens JA, Atkins D, Zhang Y, Sweep FCG, Harbeck N, Paradiso A, Cufer T, Klijn J, Wang Y[Volltext]
Meeting Abstract
(PO037)
[Volltext]
Capecitabine (Xeloda®) in the therapy of metastatic breast cancer
Eschenburg H[Volltext]
Meeting Abstract
(PO038)
[Volltext]
The combination of mitomycin, 5-fluorouracil and folinate (MiFoFU) is an effective and tolerable chemotherapy regimen in the palliative treatment of patients with metastatic breast cancer and reduced performance
Eichbaum MHR, Gast AS, Bruckner T, Schneeweiss A, Sohn C[Volltext]
Meeting Abstract
(PO039)
[Volltext]
Case Management as Cross-Sectoral Health Care Provision for Women with Breast Cancer
Thorenz A, Rottscheidt C[Volltext]
Meeting Abstract
(PO040)
[Volltext]
Integration of lymphedema care in long term follow up for breast cancer patients
Bani M, Eder I, Bani H, Engel J, Lux MP, Allali F, Kreis H, Beckmann K, Breuel C, Beckmann MW, Fasching PA[Volltext]
Meeting Abstract
(PO041)
[Volltext]
The fate of disseminated tumor cells in bone marrow of primary breast cancer patients after adjuvant systemic therapy
Becker S, Pergola G, Wallwiener D, Solomayer E, Fehm T[Volltext]
Meeting Abstract
(PO042)
[Volltext]
Benefit from participation in clinical trials
Genss EM, Janni W, Kiechle M, Sommer H, Rack B, Gauger K, Heinrigs M, Steinfeld D, Augustin D, Simon W, Harbeck N, Strobl B, Dian D, Friese K[Volltext]
Meeting Abstract
(PO043)
[Volltext]
Retrospective analysis of the efficacy of fulvestrant therapy in patients with heavily pretreated metastatic breast cancer
Beau U, Schumann C, Strauß HG, Bojara G, Grosse R, Thomssen C[Volltext]
Meeting Abstract
(PO044)
[Volltext]
MiX – first results of the ongoing prospective, multi-centre, phase II study
Lux MP, Weiß J, Sommer H, Scharl A, Beckmann K, Kreis H, Beckmann MW, Fasching PA[Volltext]
Meeting Abstract
(PO045)
[Volltext]
Long-Term Survival with Metastatic Breast Cancer: First Results of a Retrospective Analysis of Patients Treated at the West German Cancer Center (University of Essen Medical School)
Seeber S, Pohlkamp C, Welt A, Walter C, Trarbach T, Lehnerdt C, Hense J, Hügle U, Scheulen ME[Volltext]
Meeting Abstract
(PO046)
[Volltext]
Anemia therapy with Epoetin beta in adjuvant breast cancer treatment and evaluation of transferrinsaturation (TSAT)
Tessen HW, Nettelnbreker EM, Hesse A, Busch C[Volltext]
Meeting Abstract
(PO047)
[Volltext]
First analysis of the event-free survival of the GeparDuo-study: neoadjuvant doxorubicin / cyclophosphamide followed by docetaxel (AC-Doc) versus dose-dense doxorubicin and docetaxel (ADoc) in breast cancer
Blohmer JU, Kaufmann M, Eiermann W, Schütte M, Hilfrich J, Gerber B, Eidtmann H, Lampe D, Jackisch C, du Bois A, Loibl S, Zuna I[Volltext]
Meeting Abstract
(PE048)
[Volltext]
Totally Implantable Venous Access Port Systems for Patients Receiving Chemotherapy for Gynecological or Breast Malignancies: a Prospective Clinical Trial Examining the Safety, Efficacy and Impact on Quality of Life
Kreis H, Löhberg C, Lux MP, Beckmann K, Ackermann S, Lang W, Beckmann MW, Fasching PA[Volltext]
Meeting Abstract
(PE049)
[Volltext]
Fulvestrant (Faslodex®) – Outcomes of the Expanded Access Programme (EAP) with ZD9238 (Fulvestrant) in Germany for postmenopausal patients with hormone sensitive, metastatic breast cancer after progression under hormone therapy
Gieseking F, Kleeberg U, Jonat W, Illiger HJ, Harbeck N, Lück HJ[Volltext]
Meeting Abstract
(PE050)
[Volltext]
Outpatient care in metastatic breast cancer
Weide R, Arndt H, Pandorf A, Thomalla J, Heymanns J, Köppler H[Volltext]
Meeting Abstract
(PE051)
[Volltext]
KoLeDo - a prospective randomized monocenter phase 2 trial investigating 6 x CMF versus 4 x EC chemotherapy in the adjuvant setting of breast cancer therapy in postmenopausal women
Baeuerle M, Berg S, Marre E, Kreienberg R, Volm T[Volltext]
Meeting Abstract
(PE052)
[Volltext]
Infusion therapy with a high dose of 5-fluorouracil/sodium-folinate in combination with mitomycin C (MMC): a dose escalation study (phase I) for patients with metastatic breast cancer
Tauchert S, Maltaris T, Ertan K, Diedrich K, Schmitt W, Friedrich M[Volltext]
Meeting Abstract
(PE053)
[Volltext]
Cellular immunotherapy with reactivated autologous Memory T-Cells from bone marrow in late stage breast cancer patients
Schütz F, Ehlert K, Schneeweiss A, Sohn C, Schirrmacher V, Beckhove P[Volltext]
